ArticleInternational journal of general medicine2011
Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management of the common cold.
Article in International journal of general medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Garlic for the common cold.The Cochrane database of systematic reviews · 2014Pooled it
- Echinacea for preventing and treating the common cold.The Cochrane database of systematic reviews · 2014Pooled it
- Trial
- A manual acupuncture treatment attenuates common cold and its symptoms: a case series report from South Korea.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2016Trial
- Echinacea Reduces Antibiotics by Preventing Respiratory Infections: A Meta-Analysis (ERA-PRIMA).Antibiotics (Basel, Switzerland) · 2024Review
- Pharmacist's recommendations of over-the-counter treatments for the common cold - analysis of prospective cases in Poland.BMC family practice · 2021Article
- Micronutrients and bioactive substances: Their potential roles in combating COVID-19.Nutrition (Burbank, Los Angeles County, Calif.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the potential efficacy and tolerability of a natural multiherbal formula (Immumax) containing Echinacea extract 120 mg, garlic powder 100 mg, Nigella sativa oil 200 mg, and Panax ginseng extract 50 mg plus vitamin C 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the common cold. DESIGN AND
settingThe study was conducted in a prospective, double-blind, randomized, controlled study design in an outpatient setting. PATIENTS AND
methodsSixty-two eligible patients with symptoms of the common cold were randomized to either Immumax or placebo treatment groups for the duration of their symptoms or a maximum of 14 days. Resolution rates were estimated using Kaplan-Meier analysis, and resolution profiles were compared between groups using the log-rank test. The mean percentage change in total symptom severity scores at days 4 and 8 from baseline were compared between the two groups by one-way analysis of variance (ANOVA).
resultsThe median (interquartile range) time to resolution of all symptoms was 8 (5-9) days in the placebo group and 4 (3-6) days in the Immumax group. The results of the log-rank test indicate that symptoms resolved significantly faster in the Immumax group than in the placebo group (P < 0.001). The mean percentage reduction in total symptom severity scores from baseline at days 4 and 8 was significantly greater in the Immumax group than in the placebo group by one-way ANOVA (P < 0.01).
conclusionWe can conclude from our study that Immumax is helpful in reducing the duration and severity of common cold symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.